What to Watch for in Biotech Earnings This Week

Several top biotechs will report earnings this week. Will they reignite the biotech rally or drive share prices even lower?

Apr 21, 2014 at 6:30PM

Biotech stocks started the year off on a tear but have moved lower lately in dramatic fashion. For instance, the iShares Nasdaq Biotech Index (NASDAQ:IBB) is now down over 2% for the year, after gaining double digits at one point in early February. Pundits and prognosticators alike have generally attributed this recent weakness among biotechs to two issues: conservative 2014 guidance by leading names such as Celgene (NASDAQ:CELG) and Gilead Sciences (NASDAQ:GILD), and political pressure on drug pricing stemming from Gilead's hepatitis C drug Sovaldi. Investors are particularly worried that the pricing debate that started with Sovaldi could spread to the entire industry, putting significant pressure on forward earnings.

Looking ahead, one school of thought is that this pullback is ephemeral and first-quarter earnings will reignite the rally among biotech stocks. Given that several top biotech names are set to report earnings this week, this hypothesis will certainly be put to the test. Here is a quick rundown of some of the key names to keep tabs on this week:

  • Amgen (NASDAQ:AMGN) -- reports Tuesday, April 22, after the bell
  • Biogen (NASDAQ:BIIB) -- reports Wednesday, April 23, before the bell
  • Celgene -- reports Thursday, April 24, before the bell
  • Gilead -- reports Tuesday, April 22, after the bell

Will earnings matter?
Although I'm throwing in with the optimists in that we will see a number of significant beats on earnings this week, I'm not sure it will matter, and here's why. First off, we've known that Sovaldi prescriptions were off the chart for some time, but this has done nothing to shore up Gilead's share price. 

So I don't think even significant earnings beats among these four top biotechs will matter, unless we hear two statements this week. First, I believe the market wants to hear that Sovaldi's price will remain roughly the same for the foreseeable future, calming concerns over a general debate on drug pricing. My view is that the market appears to not care much about what has already transpired in terms of sales (shown by the lack of a reaction to Sovaldi prescription numbers during the quarter) and wants to know more about what revenues will look like going forward. And that leads into the second outstanding issue.

My personal belief is that the market wants to hear some of these top names and their analysts up their guidance for 2014, especially Celgene and Gilead after their anemic guidance earlier in the year. If you recall, Gilead didn't even include Sovaldi sales in its 2014 guidance.

If we don't get positive news on these outstanding issues this week, my view is that this moody market will drag biotechs down further, regardless of how amazing first-quarter earnings turn out to be. To illustrate my point, let's consider some of the growth coming out of these top names in biotech, in light of the recent industrywide downturn.  

Biotechs are growing earnings by double digits
Biotechs have been growing earnings at a truly astounding pace -- potentially justifying their two year-long-plus rally. Gilead, for example, could grow earnings by 100% year over year in 2014 based on Sovaldi sales! Growth like that is typically found in only small-cap companies transitioning from a developmental to a commercial operation, so this situation is truly unique, in my opinion.

Moreover, Amgen has consistently been beating earnings estimates based on double-digit sales growth for both Xgeva and Prolia. And a regulatory approval for its experimental cholesterol drug evolocumab would add even more fuel to this proverbial fire. Like Amgen, Biogen also has a series of earnings beats on the line come Wednesday, propelled mainly by its multiple sclerosis drug Tecfidera. What you should bear in mind is that year-over-year earnings growth is expected to come in at a stately 24% for Biogen. Finally, Celgene is projected to report year-over-year top-line growth of over 17% on Thursday, based on growing sales of both Abraxane and Revlimid. In sum, these top biotechs are all generating substantial growth that's hard to find in other industries, so the overall downtrend is, at least partly, related to emotional factors over uncertainty, not fundamentals. 

Foolish wrap-up
Looking into the mind's eye of Mr. Market, my belief is that he wants to be reassured that such strong growth is actually possible from large-cap companies. Put another way, we are facing a test of sentiment come first-quarter earnings. To date, Mr. Market has been unsure when it comes to the projections for 2014 earnings from top names like Celgene and Gilead, punishing their share prices in the process. So it's up to the management of these bellwether companies, in my opinion, to assuage these fears moving forward. 

3 stocks poised to be multi-baggers
The one sure way to get wealthy is to invest in a groundbreaking company that goes on to dominate a multibillion-dollar industry. Our analysts have found multi-bagger stocks time and again. And now they think they've done it again with three stock picks that they believe could generate the same type of phenomenal returns. They've revealed these picks in a new free report that you can download instantly by clicking here now.


George Budwell owns shares of Gilead Sciences. The Motley Fool recommends Celgene and Gilead Sciences. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Money to your ears - A great FREE investing resource for you

The best way to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as “binge-worthy finance.”

Feb 1, 2016 at 5:03PM

Whether we're in the midst of earnings season or riding out the market's lulls, you want to know the best strategies for your money.

And you'll want to go beyond the hype of screaming TV personalities, fear-mongering ads, and "analysis" from people who might have your email address ... but no track record of success.

In short, you want a voice of reason you can count on.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich," rated The Motley Fool as the #1 place online to get smarter about investing.

And one of the easiest, most enjoyable, most valuable ways to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as "binge-worthy finance."

Whether you make it part of your daily commute or you save up and listen to a handful of episodes for your 50-mile bike rides or long soaks in a bubble bath (or both!), the podcasts make sense of your money.

And unlike so many who want to make the subjects of personal finance and investing complicated and scary, our podcasts are clear, insightful, and (yes, it's true) fun.

Our free suite of podcasts

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. The show is also heard weekly on dozens of radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable. Rule Breaker Investing and Answers are timeless, so it's worth going back to and listening from the very start; the other three are focused more on today's events, so listen to the most recent first.

All are available for free at www.fool.com/podcasts.

If you're looking for a friendly voice ... with great advice on how to make the most of your money ... from a business with a lengthy track record of success ... in clear, compelling language ... I encourage you to give a listen to our free podcasts.

Head to www.fool.com/podcasts, give them a spin, and you can subscribe there (at iTunes, Stitcher, or our other partners) if you want to receive them regularly.

It's money to your ears.


Compare Brokers